Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
OnCARlytics by Imugene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
OnCARlytics is under clinical development by Imugene and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
OnCARlytics by Imugene for Melanoma: Likelihood of Approval
OnCARlytics is under clinical development by Imugene and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
OnCARlytics by Imugene for Breast Cancer: Likelihood of Approval
OnCARlytics is under clinical development by Imugene and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...
OnCARlytics by Imugene for Ovarian Cancer: Likelihood of Approval
OnCARlytics is under clinical development by Imugene and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
OnCARlytics by Imugene for Solid Tumor: Likelihood of Approval
OnCARlytics is under clinical development by Imugene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...